GeneMatrix Inc (109820) - Net Assets
Based on the latest financial reports, GeneMatrix Inc (109820) has net assets worth ₩18.32 Billion KRW (≈ $12.41 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩28.03 Billion ≈ $19.00 Million USD) and total liabilities (₩9.72 Billion ≈ $6.59 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 109820 total assets for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩18.32 Billion |
| % of Total Assets | 65.33% |
| Annual Growth Rate | 1.55% |
| 5-Year Change | -42.42% |
| 10-Year Change | 91.56% |
| Growth Volatility | 36.7 |
GeneMatrix Inc - Net Assets Trend (2011–2024)
This chart illustrates how GeneMatrix Inc's net assets have evolved over time, based on quarterly financial data. Check 109820 tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for GeneMatrix Inc (2011–2024)
The table below shows the annual net assets of GeneMatrix Inc from 2011 to 2024. For live valuation and market cap data, see GeneMatrix Inc market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩19.23 Billion ≈ $13.03 Million |
-16.94% |
| 2023-12-31 | ₩23.15 Billion ≈ $15.69 Million |
-4.29% |
| 2022-12-31 | ₩24.19 Billion ≈ $16.39 Million |
-25.17% |
| 2021-12-31 | ₩32.32 Billion ≈ $21.90 Million |
-3.21% |
| 2020-12-31 | ₩33.39 Billion ≈ $22.63 Million |
+118.98% |
| 2019-12-31 | ₩15.25 Billion ≈ $10.33 Million |
+40.76% |
| 2018-12-31 | ₩10.83 Billion ≈ $7.34 Million |
-2.04% |
| 2017-12-31 | ₩11.06 Billion ≈ $7.49 Million |
-11.41% |
| 2016-12-31 | ₩12.48 Billion ≈ $8.46 Million |
+24.37% |
| 2015-12-31 | ₩10.04 Billion ≈ $6.80 Million |
-15.57% |
| 2014-12-31 | ₩11.89 Billion ≈ $8.06 Million |
-6.98% |
| 2013-12-31 | ₩12.78 Billion ≈ $8.66 Million |
-8.18% |
| 2012-12-31 | ₩13.92 Billion ≈ $9.43 Million |
-11.57% |
| 2011-12-31 | ₩15.74 Billion ≈ $10.67 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to GeneMatrix Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2144663611000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩10.20 Billion | 53.03% |
| Other Components | ₩30.48 Billion | 158.51% |
| Total Equity | ₩19.23 Billion | 100.00% |
GeneMatrix Inc Competitors by Market Cap
The table below lists competitors of GeneMatrix Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Silverline Endustri ve Ticaret AS
IS:SILVR
|
$18.97 Million |
|
Ras Technology Holdings Ltd
AU:RTH
|
$18.97 Million |
|
BIO UV Group
PA:ALTUV
|
$18.98 Million |
|
Israel Op L
TA:ISOP
|
$18.98 Million |
|
L&P Global Berhad
KLSE:0268
|
$18.97 Million |
|
Welcron Company Limited
KQ:065950
|
$18.96 Million |
|
Hubei Geoway Investment Co Ltd
SHG:600462
|
$18.96 Million |
|
Getin Holding SA
WAR:GTN
|
$18.96 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in GeneMatrix Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 23,148,242,030 to 19,227,336,450, a change of -3,920,905,580 (-16.9%).
- Net loss of 3,748,057,580 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-3.75 Billion | -19.49% |
| Other Changes | ₩-172.85 Million | -0.9% |
| Total Change | ₩- | -16.94% |
Book Value vs Market Value Analysis
This analysis compares GeneMatrix Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.46x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.72x to 1.46x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩814.65 | ₩1402.00 | x |
| 2017-12-31 | ₩721.74 | ₩1402.00 | x |
| 2018-12-31 | ₩675.66 | ₩1402.00 | x |
| 2019-12-31 | ₩845.72 | ₩1402.00 | x |
| 2020-12-31 | ₩1672.63 | ₩1402.00 | x |
| 2021-12-31 | ₩1618.95 | ₩1402.00 | x |
| 2022-12-31 | ₩1211.46 | ₩1402.00 | x |
| 2023-12-31 | ₩1159.49 | ₩1402.00 | x |
| 2024-12-31 | ₩963.09 | ₩1402.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently GeneMatrix Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -19.49%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -37.41%
- • Asset Turnover: 0.35x
- • Equity Multiplier: 1.48x
- Recent ROE (-19.49%) is below the historical average (-13.76%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -10.98% | -16.82% | 0.39x | 1.67x | ₩-2.15 Billion |
| 2015 | -23.28% | -38.01% | 0.26x | 2.40x | ₩-2.89 Billion |
| 2016 | -30.26% | -74.35% | 0.26x | 1.55x | ₩-5.03 Billion |
| 2017 | -13.29% | -28.32% | 0.29x | 1.60x | ₩-2.58 Billion |
| 2018 | -28.68% | -65.61% | 0.15x | 2.91x | ₩-4.19 Billion |
| 2019 | -8.96% | -27.06% | 0.18x | 1.87x | ₩-2.89 Billion |
| 2020 | 24.05% | 50.50% | 0.42x | 1.14x | ₩4.69 Billion |
| 2021 | -3.06% | -8.16% | 0.31x | 1.22x | ₩-4.22 Billion |
| 2022 | -33.54% | -72.33% | 0.35x | 1.32x | ₩-10.53 Billion |
| 2023 | -3.87% | -9.12% | 0.31x | 1.35x | ₩-3.21 Billion |
| 2024 | -19.49% | -37.41% | 0.35x | 1.48x | ₩-5.67 Billion |
Industry Comparison
This section compares GeneMatrix Inc's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $92,750,551,270
- Average return on equity (ROE) among peers: -30.71%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| GeneMatrix Inc (109820) | ₩18.32 Billion | -10.98% | 0.53x | $18.97 Million |
| NSN Co. Ltd (031860) | $22.41 Billion | -58.34% | 1.03x | $12.68 Million |
| JOONGANG DNM Co.Ltd (051980) | $24.94 Billion | -48.53% | 1.23x | $71.68 Million |
| Genoray Co. Ltd (122310) | $95.53 Billion | 13.07% | 0.30x | $27.17 Million |
| Green Cross Lab Cell Corporation (144510) | $538.46 Billion | 4.53% | 0.26x | $129.54 Million |
| Optipharm.CO.LTD (153710) | $30.96 Billion | -9.95% | 0.33x | $47.22 Million |
| Cancer Rop Co. Ltd. (180400) | $29.05 Billion | -1.65% | 0.02x | $143.75 Million |
| Cytogen Inc (217330) | $18.34 Billion | -26.66% | 0.54x | $46.59 Million |
| Gencurix Inc (229000) | $12.00 Billion | -160.46% | 1.79x | $24.07 Million |
| P&K Skin Research Center Co. Ltd (347740) | $63.07 Billion | 11.56% | 0.06x | $33.47 Million |
About GeneMatrix Inc
GeneMatrix Inc. develops diagnostic products for various diseases in the field of molecular diagnostics. The company offers products for hepatitis B, hepatitis C, cervical cancer, sexually transmitted infections, respiratory infections, and gastrointestinal infections; vaccines for preventing various diseases; and new natural pharmaceutical materials for health enhancement and treatment. It also … Read more